echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > CStone's Pratinib Capsules Announces Efficacy and Safety Data in the Treatment of NSCLC Chinese Patients

    CStone's Pratinib Capsules Announces Efficacy and Safety Data in the Treatment of NSCLC Chinese Patients

    • Last Update: 2021-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 9, CStone Pharmaceuticals announced that at the 2021 World Lung Cancer Conference (2021 IASLC WCLC) organized by the International Association for the Study of Lung Cancer, the company announced the selective RET inhibitor Pugeta® (Platin) in the form of an oral report.


    The ARROW study (ClinicalTrials.


    Effectiveness: Regardless of whether it has been treated in the past, Pugeta® has achieved rapid and long-lasting clinical activity in Chinese patients with RET fusion-positive advanced NSCLC

    Patients who have previously received platinum-based chemotherapy (n=33.


    The confirmed objective response rate (ORR) was 66.


    Among 22 patients with confirmed remission, the median time to first remission was 1.


    Patients who have not received systemic treatment (n=30.


    The confirmed ORR was 80%, including 2 cases of complete remission and 22 cases of partial remission, and the DCR was 86.


    Among 24 patients with confirmed remission, the median time to first remission was 1.


    Safety: Pugeta® is well tolerated and safety is controllable

    Pugeta® is well tolerated, and is overall safe and controllable in Chinese patients, and no new safety signals have been found


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.